Bath & Body Works (BBWI) delivered mixed results in Q2 FY2027 on revenue of $1.5B versus the $1.5B estimate (-2.3% YoY) and EPS of $0.62. The next Bath & Body Works (BBWI) earnings date is Nov 19, 2026. Below is the full Bath & Body Works earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
Bath & Body Works (BBWI) Earnings Analysis — key stats
Next earnings date
Nov 19, 2026
Latest reported quarter
Q2 FY2027
Earnings verdict
Mixed
EPS beat rate
6 of last 8 (quarters above estimate)
Avg next-day move
±11.6% (over the last 8 reports)
Post-earnings direction
Up 3 / Down 5 (of the last 8 reports)
Implied move (next report)
±15.3% (options-derived · into Nov 19, 2026)
Institutional ownership
103.5% (13F as of 2026-06-30)
Top 10 holders
51.4% (of shares outstanding)
Insider activity
10 buys / 1 sells (recent Form 4 filings)
Revenue
$1.5B (vs $1.5B est · +1.1% surprise · -2.3% YoY)
EPS
$0.62 (vs $0.24 est · +155.2% surprise · +93.3% YoY)
Share price
$20.91 (-3.2%)
Market cap
$4.2B
Bath & Body Works (BBWI) Earnings Analysis — beat / miss history
Quarter
Revenue
EPS
EPS surprise
Next-day move
Verdict
Q2 FY2027
$1.5B vs $1.5B est
$0.62 vs $0.24 est
+155.2%
+6.1%
Mixed
Q1 FY2027
$1.4B vs $1.4B est
$0.32 vs $0.29 est
+9.8%
+14.8%
Mixed
Q1 FY2027
$2.7B vs $2.6B est
$2.05 vs $1.77 est
+15.8%
-0.6%
Beat
Q3 FY2026
$1.6B vs $1.6B est
$0.35 vs $0.38 est
-8.4%
-29.4%
Mixed
Q2 FY2026
$1.5B vs $1.6B est
$0.37 vs $0.37 est
+0.0%
-7.4%
Mixed
Q1 FY2026
$1.4B vs $1.4B est
$0.49 vs $0.42 est
+17.3%
-7.7%
Mixed
Q4 FY2025
$2.8B vs $1.4B est
$2.09 vs $2.04 est
+2.5%
-11.8%
Beat
Q3 FY2025
$1.6B vs $1.6B est
$0.49 vs $0.47 est
+4.3%
+14.7%
Mixed
Top institutional holders
Holder
% outstanding
Shares
Value
QoQ change
Fmr LLC
10.4%
21.0M
$486.7M
+0.7%
Blackrock, INC.
9.6%
19.4M
$449.1M
+0.5%
Vanguard Portfolio Management LLC
8.4%
17.0M
$393.6M
+13.3%
Vanguard Capital Management LLC
4.5%
9.1M
$209.7M
-1.0%
D. E. Shaw & CO., INC.
3.8%
7.7M
$178.8M
-18.7%
Aqr Capital Management LLC
3.8%
7.6M
$173.2M
-30.8%
State Street Corp
3.5%
7.1M
$165.2M
+2.9%
Alliancebernstein L.P.
2.8%
5.6M
$104.7M
-2.4%
Citadel Advisors LLC
2.5%
5.1M
$118.1M
+146.4%
American Century Companies INC
2.0%
4.1M
$94.7M
-8.5%
Recent insider transactions
Insider
Role
Date
Type
Shares
Value
Nash Sarah E
director
2026-10-16
Sell
1
$14
Heaf Daniel
director, officer: CEO
2026-09-21
Buy
591K
—
Aber Ann
officer: Chief Legal Officer &Corp Secy
2026-08-10
Buy
13K
—
Aber Ann
officer
2026-07-20
Other
0
—
Voskuil Steven E
director
2026-06-11
Buy
8K
—
Rajlin Juan
director
2026-06-11
Buy
8K
—
Symancyk James Kevin
director
2026-06-11
Buy
8K
—
Lee Danielle M.
director
2026-06-11
Buy
8K
—
What you'll find
Next Bath & Body Works (BBWI) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Bath & Body Works reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Bath & Body Works (BBWI)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Bath & Body Works's next earnings date?
Bath & Body Works's (BBWI) next scheduled earnings date is Nov 19, 2026. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Bath & Body Works (BBWI) beat or miss earnings?
In Q2 FY2027, Bath & Body Works (BBWI) posted mixed results — revenue of $1.5B versus the $1.5B estimate (+1.1% surprise) and EPS of $0.62 versus $0.24 expected (+155.2% surprise). Magnisto decodes every Bath & Body Works (BBWI) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
How often does Bath & Body Works beat earnings estimates?
Over its last 8 reported quarters, Bath & Body Works (BBWI) beat Wall Street EPS estimates 6 times, most recently a mixed result in Q2 FY2027. Magnisto tracks every Bath & Body Works (BBWI) quarter's revenue and EPS versus consensus and grades each one Beat, Miss, In-line or Mixed at a unified ±2% threshold.
How much does Bath & Body Works stock move after earnings?
Over its last 8 quarterly reports, Bath & Body Works (BBWI) moved an average of ±11.6% the day after earnings — ranging from -29.4% (Q3 FY2026) to +14.8% (Q1 FY2027). The stock rose after 3 of those 8 reports and fell after 5. Heading into its next report on Nov 19, 2026, options-implied volatility is pricing in a move of roughly ±15.3% (derived). Magnisto tracks the realized post-earnings move for every Bath & Body Works (BBWI) quarter alongside the beat/miss verdict — past moves don't predict the next one.
Who are the largest shareholders of Bath & Body Works?
Institutions hold about 103.5% of Bath & Body Works's (BBWI) shares outstanding as of the 2026-06-30 13F quarter. Its largest institutional holders include Fmr LLC (10.4%), Blackrock, INC. (9.6%), Vanguard Portfolio Management LLC (8.4%). Magnisto lists Bath & Body Works's (BBWI) top 13F holders with each stake size and its quarter-over-quarter change.
Are insiders buying or selling Bath & Body Works (BBWI)?
In the most recent Form 4 filings Magnisto tracks, Bath & Body Works (BBWI) insiders recorded 10 purchases and 1 sale — net buying. Insider transactions are one signal among many and are often routine (option exercises or scheduled 10b5-1 sales), so Magnisto shows the raw feed for you to judge.
What is the forecast for Bath & Body Works (BBWI) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Bath & Body Works (BBWI), anchored to the current $20.91 share price, so you can weigh the bull, base and bear cases for Bath & Body Works side by side.
Is Bath & Body Works (BBWI) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Bath & Body Works fits your own thesis and risk profile. This is research, not investment advice.